1 study on Octreotide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This research identifies SSTR2 as a highly promising therapeutic target for aggressive SDHB-deficient pheochromocytomas and paragangliomas, offering a novel strategy for a disease with limited options. The fact that S…